|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 25/09/2017 | |
Bruno Schick
BRD | Director/Board Member | - | 25/09/2017 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +1.81% | +2.25% | +13.63% | +81.62% | 48B | ||
| -2.54% | +3.72% | +66.86% | +116.52% | 36.89B | ||
| +0.15% | +1.26% | -3.64% | +44.11% | 12.37B | ||
| +3.71% | +3.56% | +13.95% | +98.68% | 11.95B | ||
| +0.39% | +0.58% | +32.90% | +120.94% | 9.01B | ||
| +0.66% | -0.57% | +19.74% | +46.69% | 7.2B | ||
| +0.71% | +1.75% | +52.67% | -6.28% | 7.05B | ||
| +9.99% | +32.94% | -15.50% | +25.64% | 6.58B | ||
| +0.68% | +2.63% | +20.79% | +240.34% | 6.55B | ||
| Average | +1.56% | +3.62% | +22.38% | +85.36% | 15.13B | |
| Weighted average by Cap. | +0.81% | +3.15% | +28.07% | +89.74% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















